ZOM - ZOM

Zomedica (AMEX:ZOM) Stock, Quote.Headers.trade-ideas

Zomedica

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

NRDY

More Than $9M Bet On Nerdy? Check Out These 3 Penny Stocks Executives Are Aggressively Buying

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Equities

Zomedica Corp. expands into Costa Rica with SIRE Veterinario as exclusive distributor. Strategic partnership aims to bring advanced veterinary solutions to local veterinarians.

Zomedica Taps Into Costa Rica With Strategic Partnership With SIRE Veterinario

Penny stock tips cover

Pre-Market Outlook

ACRS

CATX

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Zomedica Corp

General

ANSS

Ansys  And TSMC Announce Pilot With Microsoft To Speed Up Simulation And Analysis Of Silicon Photonic Components

MULN

Mullen CEO David Michery Provides Shareholders With Update On Sales Growth, $100M Financing, And New Vehicle Orders; Highlights Volt Mobility $210M Deal, U.S. Dealer Expansion, And Bollinger Electric Truck Production

Contracts

TBLA

Taboola Extends Partnership With Xiaomi's International Internet Business Arm

<p><strong>Providing continuing support for the SHDSL product portfolio</strong></p>


Rochester Electronics And MaxLinear Partner For Ongoing Lifecycle Support

WIIM

SEEL

Seelos Therapeutics shares are trading higher after the company announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense's military and veterans adaptive platform clinical trial for PTSD.

<p>Jefferies  analyst Stephanie Wissink   assumes Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Hold rating and raises Price Target to $76.</p>


Price Target

Initiation

Analyst Ratings

Jefferies Assumes Prestige Consumer at Hold, Raises Price Target to $76

Gainsight And SAP Announce Strategic Partnership To Boost Customer Retention And Revenue Growth Through Integration Of Gainsight CS And SAP Sales Cloud, Unifying Customer Experience Across Teams

<p>Maxim Group  analyst Jason McCarthy   upgrades Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Hold to Buy and announces $12 price target.</p>


Upgrades

MESO

Maxim Group Upgrades Mesoblast to Buy, Announces $12 Price Target

BBGI

Beasley Broadcast Shares Resume Trade

<p>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) reported quarterly losses of $(0.03) per share. This is a 900 percent decrease over losses of $(0.00) per share from the same period last year.  The company reported $60.51 million in sales this quarter. This is a 44.75 percent increase over sales of $41.81 million the same period last year.</p>


Earnings

SOS H1 EPS $(0.0299) Down From $(0.0031) YoY, Sales $60.51M Up From $41.81M YoY

ONCO

Onconetix, Inc Shares Resume Trade

<p>In the preceding three months, 7 analysts have released ratings for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $227.57, accompanied by a high estimate of $280.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.68% from the previous average price target of $219.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182881_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$280.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$206.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$251.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$204.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ResMed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ResMed analyst ratings.</strong></a></p>
<h2>Discovering ResMed: A Closer Look</h2>
<p>ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.</p>
<h3>ResMed: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> ResMed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.01%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> ResMed's net margin excels beyond industry benchmarks, reaching <strong>23.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> ResMed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.16%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.27%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> ResMed's debt-to-equity ratio is below the industry average. With a ratio of <b>0.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: ResMed Through The Eyes Of 7 Analysts

<p>In the latest quarter, 14 analysts provided ratings for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $177.5, a high estimate of $190.00, and a low estimate of $161.00. This upward trend is apparent, with the current average reflecting a 3.04% increase from the previous average price target of $172.27.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182872_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Procter &amp; Gamble by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$174.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$186.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Michael Pohn</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$179.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$175.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$189.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$161.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$174.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$177.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Procter &amp; Gamble. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Procter &amp; Gamble's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Procter &amp; Gamble analyst ratings.</strong></a></p>
<h2>Delving into Procter &amp; Gamble's Background</h2>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.</p>
<h3>Unraveling the Financial Story of Procter &amp; Gamble</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Procter &amp; Gamble's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-0.1%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Procter &amp; Gamble's net margin is impressive, surpassing industry averages. With a net margin of <strong>14.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Procter &amp; Gamble's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>6.2%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.53%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.67</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Procter & Gamble: Insights From 14 Analyst Reviews

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.5, along with a high estimate of $19.00 and a low estimate of $18.00. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182845_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of NeoGenomics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeoGenomics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of NeoGenomics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of NeoGenomics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NEO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on NeoGenomics analyst ratings.</strong></a></p>
<h2>Discovering NeoGenomics: A Closer Look</h2>
<p>NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.</p>
<h3>NeoGenomics: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> NeoGenomics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>11.97%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-11.33%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NeoGenomics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.03%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.14%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.66</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For NeoGenomics

<p>Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $70.69, with a high estimate of $90.00 and a low estimate of $54.00. Highlighting a 14.63% decrease, the current average has fallen from the previous average price target of $82.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182837_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Procore Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Trout</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$82.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Tom Roderick</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Trout</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tom Roderick</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Procore Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Procore Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Procore Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Procore Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PCOR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Procore Technologies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Procore Technologies</h2>
<p>Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.</p>
<h3>A Deep Dive into Procore Technologies's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Procore Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>24.42%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Procore Technologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-2.22%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Procore Technologies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.52%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Procore Technologies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.33%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.06</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PCOR

Critical Insights From Procore Technologies Analyst Ratings: What You Need To Know

<p><i>Upgrades to Nuvei's suite of seamless Embedded Payments solutions unlocks new growth opportunities for businesses of all sizes</i></p>


NVEI

Nuvei For Platforms Launches New Features

RDZN

Roadzen shares are trading higher after the company announced a one-year extension for its insider lock-up period.

Macro Economic Events

Econ #s

Economics

House Price Index (MoM) (Jul) + 0.1% vs +0.2% Est.,

<p>8 analysts have shared their evaluations of Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.0, with a high estimate of $82.00 and a low estimate of $53.00. Observing a 1.04% increase, the current average has risen from the previous average price target of $68.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182824_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Dayforce by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bhavin Shah</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jared Levine</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dayforce. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dayforce compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Dayforce's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Dayforce's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dayforce analyst ratings.</strong></a></p>
<h2>About Dayforce</h2>
<p>Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.</p>
<h3>Breaking Down Dayforce's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Dayforce displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>15.69%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Dayforce's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-0.43%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dayforce's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.07%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Dayforce's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.02%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Dayforce's debt-to-equity ratio is below the industry average. With a ratio of <b>0.5</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Latest Analyst Ratings For Dayforce

<p>4 analysts have expressed a variety of opinions on Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.88, a high estimate of $8.00, and a low estimate of $4.50. This upward trend is apparent, with the current average reflecting a 23.79% increase from the previous average price target of $4.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727182810_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Compass by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Compass. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Compass compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Compass's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Compass's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COMP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Compass analyst ratings.</strong></a></p>
<h2>Delving into Compass's Background</h2>
<p>Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.</p>
<h3>Unraveling the Financial Story of Compass</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Compass displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.83%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Compass's net margin excels beyond industry benchmarks, reaching <strong>1.22%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Compass's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.68%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Compass's ROA excels beyond industry benchmarks, reaching <strong>1.75%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.32</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COMP

Key Takeaways From Compass Analyst Ratings

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Zomedica</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/zom-stock-quote/"><strong>ZOM</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Zomedica reported earnings per share of -1 cent.</li><li>The company reported revenue of $6.26 million.</li><li>This was 23.45% worse than the analyst estimate for revenue of $8.18 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/zom-stock-earnings-zomedica-for-q1-of-2024/">ZOM Stock Earnings: Zomedica Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ZOM Stock Earnings: Zomedica Misses Revenue for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The biggest pre-market stock movers are ready to go as we check out all of the hottest news on Friday morning!</p>



<p>Earnings reports continue to be a major mover of shares this morning as companies report their Q1 2024 results.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Novavax </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nvax-stock-quote/"><strong>NVAX</strong></a>) stock is rocketing more than 112% alongside its <a href="https://finance.yahoo.com/news/novavax-reports-first-quarter-2024-061500233.html">Q1 earnings report</a> and a deal with <strong>Sanofi </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/sny-stock-quote/"><strong>SNY</strong></a>).</li>



<li><strong>AEye </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aeye-stock-quote/"><strong>AEYE</strong></a>) shares are soaring over 42% with strong pre-market trading.</li>



<li><strong>Sensus Healthcare</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/srts-stock-quote/"><strong>SRTS</strong></a>) stock is surging more than 25% after <a href="https://investorplace.com/earning-results/2024/05/srts-stock-earnings-sensus-healthcare-for-q1-of-2024/?utm_source=newsbreak&amp;utm_medium=editorial">beating Q1 EPS and revenue estimates</a>.</li>



<li><strong>Carbon Revolution</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/"><strong>CREV</strong></a>) shares are rising over 18% without any clear news this morning.</li>



<li><strong>Natera </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ntra-stock-quote/"><strong>NTRA</strong></a>) stock is increasing more than 18% on <a href="https://www.marketwatch.com/amp/story/natera-shares-rise-16-after-1q-positive-cash-flow-183dc052">positive Q1 cash flow</a>.</li>



<li><strong>Sweetgreen</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/sg-stock-quote/"><strong>SG</strong></a>) shares are climbing over 16% with the release of its <a href="https://www.nasdaq.com/press-release/sweetgreen-inc.-announces-first-quarter-2024-financial-results-2024-05-09">Q1 earnings report</a>.</li>



<li><strong>Inseego </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/insg-stock-quote/"><strong>INSG</strong></a>) stock is heading more than 15% higher alongside <a href="https://www.nasdaq.com/press-release/inseego-reports-first-quarter-2024-financial-results-2024-05-09">Q1 earnings results</a>.</li>



<li><strong>Array Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/arry-stock-quote/"><strong>ARRY</strong></a>) shares are jumping over 15% with its <a href="https://www.globenewswire.com/news-release/2024/05/09/2879211/0/en/Array-Technologies-Inc-Reports-Financial-Results-for-the-First-Quarter-2024-Achieves-record-gross-margin-and-2-1-billion-of-executed-contracts-and-awarded-orders.html">latest earnings release</a>.</li>



<li><strong>SoundHound AI</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/"><strong>SOUN</strong></a>) stock is getting a more than 14% boost on <a href="https://www.investopedia.com/soundhound-ai-stock-surges-as-demand-for-voice-ai-tools-lift-annual-sales-guidance-8646393">increasing demand for its services</a>.</li>



<li><strong>Clene </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/"><strong>CLNN</strong></a>) shares are up over 13% <a href="https://www.zacks.com/stock/news/2270346/clene-inc-clnn-reports-q1-loss-lags-revenue-estimates">despite missing revenue estimates</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Macrogenics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mgnx-stock-quote/"><strong>MGNX</strong></a>) stock is crashing more than 68% on an <a href="https://finance.yahoo.com/news/macrogenics-provides-corporate-progress-first-200100560.html">operating update and earnings report</a>.</li>



<li><strong>Progyny </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pgny-stock-quote/"><strong>PGNY</strong></a>) shares are plummeting over 34% <a href="https://www.nasdaq.com/press-release/progyny-inc.-announces-first-quarter-2024-results-2024-05-09">alongside its earnings report</a>.</li>



<li><strong>Greenwave Technology Solutions</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gwav-stock-quote/"><strong>GWAV</strong></a>) stock is diving more than 27% after <a href="https://www.prnewswire.com/news-releases/greenwave-technology-solutions-expects-to-process-record-volumes-of-steel-and-copper-with-revenues-exceeding-40-million-in-2024-302140650.html">rallying on earnings yesterday</a>.</li>



<li><strong>Microvision </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/"><strong>MVIS</strong></a>) shares are taking an over 26% beating after <a href="https://investorplace.com/earning-results/2024/05/mvis-stock-earnings-microvision-for-q1-of-2024/?utm_source=newsbreak&amp;utm_medium=editorial">missing Q1 EPS estimates</a>.</li>



<li><strong>Pineapple Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pegy-stock-quote/"><strong>PEGY</strong></a>) stock is tumbling close to 22% <a href="https://www.nasdaq.com/press-release/pineapple-energy-reports-first-quarter-2024-financial-results-2024-05-09">alongside Q1 earnings</a>.</li>



<li><strong>Applied Optoelectronics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aaoi-stock-quote/"><strong>AAOI</strong></a>) shares are sliding more than 16% with its <a href="https://www.nasdaq.com/press-release/applied-optoelectronics-reports-first-quarter-2024-results-2024-05-09">Q1 2024 earnings report</a>.</li>



<li><strong>Zomedica </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/zom-stock-quote/"><strong>ZOM</strong></a>) stock is falling over 13% after <a href="https://www.msn.com/en-us/money/markets/zom-stock-earnings-zomedica-misses-revenue-for-q1-2024/ar-BB1m88cY?ocid=finance-verthp-feeds">missing Q1 revenue estimates</a>.</li>



<li><strong>Ginkgo Bioworks</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/"><strong>DNA</strong></a>) shares are dropping more than 13% on <a href="https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-first-quarter-2024-financial-results-302141730.html">lackluster Q1 revenue</a>.</li>



<li><strong>JFrog </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/frog-stock-quote/"><strong>FROG</strong></a>) stock is decreasing over 12% with its <a href="https://www.businesswire.com/news/home/20240509945856/en/JFrog-Announces-First-Quarter-2024-Results">latest earnings report</a>.</li>



<li><strong>Indie Semiconductor</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/indi-stock-quote/"><strong>INDI</strong></a>) shares close out our pre-market stock movers down nearly 12% with <a href="https://www.businesswire.com/news/home/20240509003050/en/indie-Semiconductor-Reports-First-Quarter-2024-Results">lagging earnings and revenue</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-10th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Zomedica increases manufacturing capacity

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Recent trading activity suggests that <a target="_blank" href="https://investorplace.com/stock-types/penny-stocks/"></a><a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> are in the spotlight. According to the Financial Times, stocks priced below $1 have comprised more than <a target="_blank" href="https://www.ft.com/content/c02e4317-e39d-4d0d-a80a-1fd74add72ba">14%</a> of 2024&rsquo;s trading volume thus far, illustrating the growing demand for penny stocks.</p>



<p>The question now becomes: Are penny stocks undervalued, or are speculators dominating trading volume?</p>



<p>I believe numerous penny stocks are undervalued. Moreover, if selected correctly, penny stocks provide diversification benefits. Sure, some penny stocks often possess outlying risks. However, careful screening methodologies can abate such risks, providing investors with scintillating risk-adjusted investment opportunities.</p>



<p>Given the above, I decided to search for three undervalued penny stocks. Methodologically, I emphasized fundamental attributes, valuation multiples, and technical pricing points. In addition, I overlayed the analysis with event-driven variables to ensure short-term alignment.</p>



<p>Without further ado, here are three undervalued penny stocks to consider.</p>



<h2>Most Undervalued Penny Stocks: Graham Corporation (GHM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/engineering_1600-300x169.jpg" alt="A photo of three people sitting around one end of a table, looking at a laptop screen."><div>Source: Gorodenkoff/ShutterStock.com</div></div><p><strong>Graham Corporation</strong> (NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/ghm-stock-quote/">GHM</a></strong>) operates in the engineering field, emphasizing the design and development of high-level solutions for participants in the defense, space, and energy industries.</p>



<p>Although it has been around the block for a long time, GHM stock has plenty of upside potential after realigning its corporate strategy with modern demands. Among the contributing factors to Graham Corporation&rsquo;s pivot was its <a target="_blank" href="https://www.businesswire.com/news/home/20210601005317/en/Graham-Corporation-Acquires-Barber-Nichols-Inc.-for-70-million">acquisition of</a> aerospace equipment supplier Barber-Nichols in 2021. Moreover, Graham Corporation <a target="_blank" href="https://www.nasdaq.com/articles/graham-acquires-p3-technologies-terms-undisclosed">acquired</a> P3 Technologies last year to add key turbo propulsion synergies to its Barber-Nichols unit.</p>



<p>Furthermore, GHM stock&rsquo;s short-term variables are well-placed. For instance, Graham Corporation&rsquo;s fourth-quarter earnings report impressed after the firm exceeded its quarterly revenue estimate by <a target="_blank" href="https://seekingalpha.com/news/4113990-graham-non-gaap-eps-of-015-revenue-of-491m-beats-by-46m-initiates-fy25-outlook?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A4">$4.6 million</a>. Additionally, Graham Corporation recently sealed <a target="_blank" href="https://ir.grahamcorp.com/news-events/press-releases/detail/358/graham-corporation-receives-17-million-of-orders-to">$17 million</a> worth of surface condenser systems orders, providing it with noteworthy pipeline revenue.</p>



<p>Lastly, GHM stock&rsquo;s valuation prospects are intact. Although its price-to-earnings ratio of <a target="_blank" href="https://www.morningstar.com/stocks/xnys/ghm/valuation">65.83x</a> is questionable, its price-to-sales ratio of 1.62x is solid. Why would I look past GHM stock&rsquo;s price-to-earnings ratio? The short answer is that Graham Corporation is blitzscaling under its new corporate strategy; therefore, I prefer emphasizing its top-line valuation.</p>



<h2>Zomedica (ZOM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/veterinarian-zom-1600-300x169.jpg" alt="ZOM stock: Persian cat with veterinarian doctor at vet clinic"><div>Source: didesign021 / Shutterstock.com</div></div><p><strong>Zomedica</strong> (NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/zom-stock-quote/">ZOM</a></strong>) is a veterinary health company operating in pet pharmaceuticals&rsquo; design, development, and commercialization. Although a frequently mentioned penny stock, Zomedica has suffered a series of declines, leading to a drawdown of more than <a target="_blank" href="https://investorplace.com/stock-quotes/zom-stock-quote/">80%</a> since its inception. However, key variables suggest ZOM stock is undervalued and ready to rumble.</p>



<p>A leading indicator has emerged, indicating a turnaround is en route. Zomedica recently announced it has increased its operating capacity by <a target="_blank" href="https://metroatlantaceo.com/news/2024/06/zomedica-increases-manufacturing-capacity-expansion-its-roswell-georgia-facility-can-support-production-five-times-current-levels/#:~:text=The%20expansion%2C%20which%20increases%20the,growing%20demand%20for%20Zomedica's%20products.">finalizing the expansion</a> of its manufacturing facility in Roswell, Georgia. This move suggests that Zomedica is ready to scale, concurrently providing its shareholders with growth prospects. Moreover, Zomedica&rsquo;s expansion adds to its tangible asset base, phasing sustainable growth into its business model.</p>



<p>Furthermore, Zomedica&rsquo;s short-term variables have improved. For example, Zomedica&rsquo;s first-quarter earnings report dropped in May, revealing <a target="_blank" href="https://seekingalpha.com/news/4104106-zomedica-gaap-eps-of-0_01-revenue-of-6_3m?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A3">$6.3 million</a> in revenue, a 14.5% year-over-year increase. Additionally, Zomedica reported $90.9 million in cash and equivalents, conveying its ability to reinvest in both tangible and intangible assets.</p>



<p>ZOM stock has a price-to-sales ratio of <a target="_blank" href="https://www.morningstar.com/stocks/xase/zom/valuation">5.66x</a>, which I deem prudent, given its illustrious three-year compound annual growth rate of <a target="_blank" href="https://seekingalpha.com/symbol/ZOM/growth">11.29x</a>.</p>



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div><p><strong>Knightscope</strong> (NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a></strong>) is a security and robotics company situated in the United States. The firm has access to secular growth prospects due to its exposure to the robotics industry, a market touted to grow by <a target="_blank" href="https://www.linkedin.com/pulse/robotics-market-projected-raise-cagr-2923-lvifc/">29.23%</a> annually until 2028. In fact, Knightscope&rsquo;s systematic support is echoed by its five-year compound annual growth rate of <a target="_blank" href="https://seekingalpha.com/symbol/KSCP/growth">31.18%</a>.</p>



<p>Another attraction to Knightscope is its contract success rate. Earlier this week, the company announced it had won a campus <a target="_blank" href="https://www.morningstar.com/news/business-wire/20240610427751/knightscope-receives-ivy-league-contract">security contract</a> from an unnamed Ivy League school. The contract announcement comes only two months after Knightscope achieved <a target="_blank" href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-wins-18-contracts-valued-over-1-million">18 new contracts</a> and five renewal agreements valued at over $1 million.</p>



<p>Furthermore, Knightscope&rsquo;s fundamental growth was communicated by its first-quarter earnings report, released three weeks ago. The company&rsquo;s quarterly revenue settled at <a target="_blank" href="https://www.msn.com/en-us/money/markets/kscp-stock-earnings-knightscope-reported-results-for-q1-2024/ar-BB1mw5sy?ocid=finance-verthp-feeds">$2.25 million</a>, which is commendable for a niche firm founded merely 11 years ago.</p>



<p>Although Knightscope has illustrated fundamental zeal, its stock has yet to reach its full potential. For example, despite its array of positive news, it remains below its 10-, 50-, 100-, and 200-day <a target="_blank" href="https://seekingalpha.com/symbol/KSCP/momentum/performance">moving averages</a>. Additionally, KSCP stock has a price-to-sales ratio of <a target="_blank" href="https://www.morningstar.com/stocks/xnas/kscp/valuation">2.03x</a>, which is low for a growth stock.</p>



<p>Some might say the above-mentioned variables signal busted growth. However, I think they explicitly convey a value opportunity!</p>



<p><em>On the date of publication, Steve Booyens did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a></em>.</p>
<div><p>Steve Booyens co-founded Pearl Gray Equity and Research in 2020 and has been responsible for cross-asset research and PR ever since. Before founding the firm, Steve spent time working in various finance roles in London and South Africa. He holds an MSc in Investment Banking from Queen Mary &ndash; University of London. Furthermore, Steve obtained his CFA Charter on April 26, 2024, and is working toward his Ph.D. in Finance. His articles are published on various reputable web pages such as Seeking Alpha, TipRanks, Yahoo Finance, and Benzinga. Steve&rsquo;s articles on InvestorPlace form an interesting juxtaposition between mainstream opinion and objective theory. Readers can expect coverage on frequently traded stocks, REITs, fixed-income funds, CEFs, and ETFs.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/the-3-most-undervalued-penny-stocks-to-buy-in-june-2024/">The 3 Most Undervalued Penny Stocks to Buy in June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Most Undervalued Penny Stocks to Buy in June 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Profiting from high-risk, high-reward stocks is a feat easier said than done. Luck can often make a big difference between a total loss and stumbling upon an unforeseen windfall. Yet, while you never know if you&rsquo;ll end up being &ldquo;early&rdquo; in the next big meme stock, there are quite a few high-upside stocks you can identify based on fundamentals.</p>



<p>Keep in mind, however, that most of these opportunities probably will not come solely from the use of a stock screener. Rather, they can be found via deep dives into the underlying companies. That said, not all of the best high-potential payoff stocks are hiding under unturned rocks.</p>



<p>Even among some popular <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> are some names with the potential to appreciate in value tenfold from current price levels. With all of this in mind, let&rsquo;s take a closer look at the following seven high-risk, high-reward stocks. Each of them falls into either one of these two categories.</p>



<h2>AmBase (ABCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/real-estate-stocks-keys-city-1600-300x169.jpg" alt="hand of person in a suit dangling keys with a house symbol on the ring. Windows overlooking city skyline in background."><div>Source: ImageFlow/shutterstock.com</div></div><p><strong>AmBase</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/abcp-stock-quote/"><strong>ABCP</strong></a></span>) is no stranger to litigation. In the early 2010s, this holding company settled a lawsuit against the U.S. Federal Government dating back to the Savings &amp; Loan Crisis, then invested a fair amount of this <a href="https://www.prnewswire.com/news-releases/ambase-announces-signed-settlement-agreement-in-supervisory-goodwill-legal-proceedings-168168346.html">$180.65 million</a> windfall into a New York City condominium project.</p>



<p>However, in 2017, the project fell into foreclosure, and AmBase&rsquo;s equity was wiped out. That was bad news for ABCP stock investors at the time, but flashing forward seven years later, it appears there&rsquo;s hope yet for speculators in this high-risk, high-reward stock. Per a February 2024 writeup from Substack publisher Under the Radars, AmBase has a <a href="https://undertheradars.substack.com/p/a-deep-dive-into-ambase">stronger-than-expected chance</a> of prevailing in its suit against the developer behind this ill-fated real estate investment.</p>



<p>The potential payoff could be massive. Even when accounting for litigation funding and related dilution, ABCP could experience a triple-digit percentage jump in price. Factoring in the potential for proceeds from litigation against the lenders on the project, a ten-fold jump may be within the realm of possibility. Although AmBase will be a total loss if it fails to see a favorable outcome in this case, for those who can handle the risk, ABCP is worth a closer look.</p>



<h2>Archer Aviation (ACHR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/achr1600-2-300x169.png" alt="Person holding cellphone with logo of American eVTOL aircraft company Archer Aviation Inc. (ACHR) on screen in front of webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Archer Aviation</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/achr-stock-quote/"><strong>ACHR</strong></a></span>) is one of the more high-profile, high-risk, high-reward stocks currently out there. As you may already know, Archer is one of several publicly traded companies looking to become a leader in the emerging vertical takeoff and landing (eVTOL) industry.</p>



<p>These stocks, sometimes referred to as &ldquo;air taxi stocks&rdquo; or <a href="https://investorplace.com/industries/consumer-discretionary/automotive/flying-cars/">&ldquo;flying car stocks.&rdquo;</a> have experienced brief waves of speculative frenzy. ACHR stock is no exception. Shares went from around $2 to as much as $7.49 per share last summer but have since pulled back to around $3.50 per share. In the near term, sideways or even negative price performance could persist. However, Archer did just recently gain <a href="https://seekingalpha.com/news/4113138-archer-aviation-stock-takes-off-after-unit-secures-faa-certification-to-operate-commercial-airline?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A4">regulatory approval</a> to operate as a commercial airline operator.</p>



<p>That bit of progress means the company is one step closer to launching its air taxi services in major markets across the world. According to analysts at <strong>JPMorgan </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/jpm-stock-quote/"><strong>JPM</strong></a></span>), this nascent industry could be worth $1 trillion annually by 2040. Even if industry growth falls far short of this forecast, chances are ACHR, which currently has a market cap of just $1.1 billion, could eventually be worth ten times what it is worth today.</p>



<h2>Barfresh Food Group (BRFH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/baby-food-300x169.jpg" alt="An image from above three cups of baby food, with little bites of vegetables scattered around them."><div>Source: Shutterstock</div></div><p><strong>Barfresh Food Group</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/brfh-stock-quote/"><strong>BRFH</strong></a></span>) is a high-upside stock I&rsquo;ve talked bullishly about recently, in my <a href="https://investorplace.com/2024/06/treasure-hunt-7-penny-stocks-wall-street-hasnt-discovered-yet/">coverage of top undiscovered stocks.</a> In a nutshell, Barfresh Food Group is a purveyor of pre-made smoothies and juices, focused primarily on serving the school lunch market.</p>



<p>After some past setbacks, the situation with Barfresh Food Group is improving rapidly. Not only is demand from its primary end-user market bouncing back in a big way, but the company could be on the verge of moving into other food service verticals. Recent news and increased attention to this stock from the online value investing community have already led to a big rebound for BRFH.</p>



<p>In a little over two months, shares have soared in value more than threefold. Even so, another many-fold move higher may not be out of the question. Reaching 10x from its current price may be somewhat of a stretch goal, yet another two or threefold run is certainly nothing to sneeze at. Consider shares worthy of a speculative buy at current prices. If Barfresh sells off after this recent rally, consider it an even stronger opportunity among high-risk stocks.</p>



<h2>Lithium Americas (LAC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/lithium-americas-lac-1600-300x169.jpg" alt="smartphone with logo of Canadian company Lithium Americas Corp on screen"><div>Source: Wirestock Creators / Shutterstock.com</div></div><p>With <a href="https://investorplace.com/industries/energy/renewable-energy/battery/lithium/">lithium stocks</a> moving from super hot to out of favor among investors, now may be the right time to make a &ldquo;lottery ticket&rdquo; wager on <strong>Lithium Americas</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/lac-stock-quote/"><strong>LAC</strong></a></span>). The company&rsquo;s primary asset is its full ownership of the Thacker Pass lithium mining project, located in northern Nevada.</p>



<p>LAC stock has fallen considerably since last October when Lithium Americas split off from its former corporate parent, <strong>Lithium Americas (Argentina) </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/laac-stock-quote/"><strong>LAAC</strong></a></span>). Chalk up LAC&rsquo;s tremendous tumble to the big drop in spot lithium prices. With spot lithium at a <a href="https://carboncredits.com/lithium-prices-plunge-to-35-month-low-amid-surging-ev-sales-june-2024/">35-month low,</a> it makes sense that there&rsquo;s not much bullishness about the potential upside from the Thacker Pass project.</p>



<p>However, as signs emerge that the recent EV sales slump <a href="https://www.bloomberg.com/news/articles/2024-05-28/the-slowdown-in-us-electric-vehicle-sales-looks-more-like-a-blip">may be little more than a short-lived blip,</a> demand for lithium, used in the production of EV batteries, could be headed for a rebound as well. That could mean big profits for LAC once Thacker Pass comes online three years from now. As InvestorPlace&rsquo;s Faisal Humayun <a href="https://finance.yahoo.com/news/3-lithium-stocks-millionaires-2030-103600888.html">pointed out</a> last month, Thacker Pass could have an after-tax net present value of $5.7 billion. LAC&rsquo;s current $577 million market cap could mean an eventual tenfold move higher for shares.</p>



<h2>Midwest Energy Emissions (MEEC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/energy-stocks-1600-300x169.png" alt="Person holding the glowing world in their hands with icons with different types of energy. AI Recommended Energy Stocks in July"><div>Source: PopTika / Shutterstock</div></div><p><strong>Midwest Energy Emissions</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/meec-stock-quote/"><strong>MEEC</strong></a></span>) was already one of the top high-risk, high-reward stocks when I last wrote about it <a href="https://investorplace.com/2024/04/if-you-can-only-buy-one-penny-stock-in-april-it-better-be-one-of-these-7-names/">back in April,</a> but at current prices, the potential for it to rise by 10x may now be far greater. Similar to AmBase, Midwest Energy Emissions is another litigation windfall stock.</p>



<p>In the case of MEEC stock, a cash windfall from litigation isn&rsquo;t merely a potential catalyst: It has already happened. Back in March, a federal court awarded a <a href="https://ir.me2cenvironmental.com/press-releases/detail/661/me2c-environmental-issues-statement-on-patent-litigation-win">$57 million</a> patent infringement verdict in favor of the company. Better yet, there may be a path to further gains, thanks to additional catalysts on tap. Midwest Energy Emissions has already started to de-lever its balance sheet, thanks to this cash infusion.</p>



<p>Also, according to Seeking Alpha commentator 1035 Capital Management, there&rsquo;s a big opportunity for Midwest Energy to use this cash to pursue growth opportunities in areas like forever chemicals and rare earth elements. Per the commentators, the litigation and growth catalysts, combined with the present value of MEEC&rsquo;s assets, could make this stock eventually worth up to $5 per share. If the stock pulls back further in the near term, the opportunity to buy in for possible 10x gains could emerge.</p>



<h2>SurgePays (SURG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/payments-300x169.jpg" alt="a person holding a smartphone over a check out scanner representing payments stocks to buy"><div>Source: Shutterstock</div></div><p><strong>SurgePays</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/surg-stock-quote/"><strong>SURG</strong></a></span>) is a fintech and telecom provider targeting what it calls the &ldquo;underbanked and underserved.&rdquo; So far this year, shares have taken a big dive due to uncertainty surrounding a U.S. Federal Government program that is material to the company&rsquo;s business and future growth prospects.</p>



<p>That is, SurgePays is a major Affordable Connectivity Program (<a href="https://investorplace.com/stock-quotes/acp-stock-quote/"><strong>ACP</strong></a>) vendor. This program subsidizes low-cost mobile internet service. However, due to a lapse in funding from Congress, <a href="https://www.fcc.gov/acp">ACP has been put on hiatus.</a> Yet, while uncertainty regarding a resolution runs high, making a &ldquo;lottery ticket&rdquo; wager on SURG stock could lead to a big payoff if federal funding resumes.</p>



<p>In the event this happens, sentiment for SurgePays could turn on a dime. Prior forecasts called for the company to earn as much as 80 cents per share in 2025. Hence, a positive turn of events would likely send this $3.19 per share stock back to double-digit price levels. Add in other catalysts, like SurgePays&rsquo; move into <a href="https://ir.surgepays.com/news-events/press-releases/#b2iLibScrollTo">prepaid wireless,</a> and there may be a longshot chance of an eventual tenfold move higher. With SURG, keep in mind the high risk, but don&rsquo;t discount the potential high rewards.</p>



<h2>Zomedica (ZOM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/veterinarian-zom-1600-300x169.jpg" alt="ZOM stock: Persian cat with veterinarian doctor at vet clinic"><div>Source: didesign021 / Shutterstock.com</div></div><p><strong>Zomedica</strong> (NYSEAMERICAN:<span><a href="https://investorplace.com/stock-quotes/zom-stock-quote/"><strong>ZOM</strong></a></span>) is another of the better-known high-risk, high-reward stocks, if only due to its brief time as a meme stock in 2021. However, unlike then, when shares went &ldquo;to the moon&rdquo; due to hope, hype and <a href="https://markets.businessinsider.com/news/stocks/zomedica-stock-price-carole-baskin-cameo-tiger-king-promoted-company-2021-1-1029961688">promotion from none other than Tiger King&rsquo;s Carole Baskin,</a> today&rsquo;s bull case for the veterinary diagnostics company is a lot more substantive.</p>



<p>At current prices, ZOM stock trades at a 38% discount to book value. As research firm Buyside Report tweeted back in May, former executives from <strong>Idexx Laboratories</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/idxx-stock-quote/"><strong>IDXX</strong></a></span>) and <strong>Heska</strong> (NASDAQ:<span><strong>HSKA</strong></span>) have <a href="https://twitter.com/buysidereport/status/1790747112013005172">joined the company&rsquo;s board and management.</a> These insiders have also been <a href="https://finviz.com/quote.ashx?t=ZOM&amp;p=d">consistently making insider purchases</a> of the stock.</p>



<p>Last year, <a href="https://www.qorvo.com/newsroom/news/2023/zomedica-announces-acquisition-of-truforma-platform-developer-qorvo-biotech-llc">Zomedica acquired Qorvo Biotech,</a> the developer of its famed Truforma veterinary diagnostics platform. Sales have steadily increased since the new management team took over. Eyeing further growth, Zomedica continues to make bolt-on acquisitions of new product offerings and just recently announced it was <a href="https://feeds.issuerdirect.com/news-release.html?newsid=5834084161599670">ramping up production capacity.</a> While it may not happen as rapidly as it did during 2021&rsquo;s &ldquo;meme mania,&rdquo; if fundamentals keep improving for ZOM, a tenfold climb higher may just well be within reach.</p>



<p><em>On the date of publication, Thomas Niel held ABCP, MEEC and ZOM. He did not hold (either directly or indirectly) any positions in the other securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines.</em></a></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Thomas Niel, contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/7-lottery-ticket-stocks-that-could-turn-1-k-into-10-k/">7 &#8216;Lottery Ticket Stocks&#8217; That Could Turn $1K into $10K</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 'Lottery Ticket Stocks' That Could Turn $1K into $10K

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

Zomedica reports Q2 results

Zomedica Pharmaceuticals (ZOM) has released an update. Zomedica Pharmaceuticals has announced a record-breaking revenue of $7.3 million for Q4 and ...

Zomedica Achieves Record Revenue and Steady Growth in 2023

Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Zomedica</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/zom-stock-quote/"><strong>ZOM</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Zomedica reported earnings per share of -1 cent.</li><li>The company reported revenue of $6.13 million.</li><li>This was 2.06% worse than the analyst estimate for revenue of $6.26 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/zom-stock-earnings-zomedica-for-q2-of-2024/">ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024

AAOI

ABCP

ACHR

AEYE

AMAT

ARRY

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

BRFH

CARA

CLNN

COCP

CREV

CSCO

CTRM

ESPR

FROG

GLNG

GOEV

GOLD

GRAB

GWAV

HUYA

IDXX

INDI

INSG

JAGX

KNDI

KSCP

LAAC

LITE

MDAI

MEEC

MGNX

MIRA

MMAT

MNDY

MVIS

NNDM

NTRA

NVAX

OGEN

OUST

PEGY

PGNY

PSFE

RRAC

SACH

SOUN

SRTS

STNE

SURG

TAYD

TCEHY

TCRT

VUZI

WKHS

XXII

Press Releases

The United States Eventing Association Names Zomedica's PulseVet(R) as the Official Shock Wave of the USEA

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference

Zomedica Introduces Enhanced Audio Features for the VETGuardian® Zero-touch Vital Signs Remote Monitoring System

Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System

Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product

Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities

Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota

Dawson James

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Zomedica

Zomedica (ZOM) Forecast

Zomedica (AMEX:ZOM) Stock, Quote.Headers.trade-ideas